Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Amphotericin B Lipid Complex | Abelcet | 4.5. Interactions with other medicinal products | Interactions with Antineoplastic agents, Corticosteroids , Corticotropin, Cyclosporin, Digitalis glycosides, Flucytosine, Imidazoles and Other nephrotoxic medications. | Mar,2023 |
| Zanubrutinib | Brukinsa | 2.3 Dosage Modifications for Drug Interactions | Avoid coadministration of Zanubrutinib with moderate Cytochrome (CYP3A4) inducers. Narrow therapeutic index medicines that are metabolized by Cytochrome (CYP3A) and Cytochrome (CYP2C19) should be used with caution with Zanubrutinib | Mar,2023 |
| Dacomitinib | Vizimpro | 4.5. Interactions with other medicinal products | Interactions with paroxetine | Mar,2023 |
| Vinorelbine | Navelbine | 4.8 Undesirable effects | Pulmonary embolism, Posterior reversible encephalopathy syndrome, Skin hyperpigmentation (serpentine supravenous hyperpigmentation) | Jan,2023 |
| Ciprofloxacin | Ciprobay | 4.5. Interactions with other medicinal products | Interactions with mycophenolate | Mar,2023 |
| Duvelisib | Copiktra | 4.5. Interactions with other medicinal products | Interactions with Cytochrome (CYP3A4) substrate | Mar,2023 |